Register for IPO Updates
Our Passion for IPOs
Largest Global IPOs
Largest US IPOs
Largest US IPOs YTD
Top First Day Returns
US IPO Stats
IPO Industry Breakdown
AWARD WINNER 2015
North American ETF Provider
Follow us on g+
Like us on Facebook
Follow us on LinkedIn
Free iPhone App
Free Android App
IPO News Feed
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
Ice Buckets and IPOs: 6 biotechs targeting CNS diseases
Analyst IPO Blog
The ALS Association
issued a press release
Tuesday stating that donations in the past month have reached $89 million, including $66 million in the past seven days. During the same time last year, it raised just $2 million, demonstrating the power of social media as the "ice bucket challenge" goes viral on Youtube, Facebook (NASDAQ: FB; up 97% since May 2012 IPO) and Twitter (NYSE:
; up 77% since November 2013 IPO).
With 51 biotech initial public offerings this year, companies in pre-revenue drug development represent the single largest segment of the IPO market in 2014 (outnumbering the combined number biotech IPOs in 2012 and 2013). Biotechs are also the largest component of upcoming IPOs in the pipeline.
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease) is a fatal neurodegenerative disease that affects about 30,000 people in the US.
Active trials to treat ALS
are ongoing, and it remains one of several central nervous system (CNS) diseases targeted by companies that have either filed to go public or completed an IPO this year.
, which originally filed to raise $5 million in June 2013, recently announced plans to list on the NASDAQ instead of the OTC Bulletin Board. A very early-stage company, it expects to launch its first clinical program studying the use of stem cells to treat ALS in early 2015. Because of its size, Q Therapeutics will not be included in Renaissance Capital's IPO stats.
Forward Pharma (
could be the year's largest biotech IPO, with a proposed deal size of $200 million. Forward Pharma filed with the SEC two weeks ago, meaning an IPO could come as early as mid-September. The Danish company is in late-stage clinical trials for a slow-release oral treatment of multiple sclerosis (MS), a CNS disease that affects an estimated 400,000 people in the US.
Vitae Pharmaceuticals (
is a recent biotech IPO filer notable for its technological approach to developing a treatment for CNS diseases including Alzheimer's and MS. The early-stage company filed to raise $55 million on August 12, and claims that its software uses artificial intelligence and sophisticated algorithms to model drug structures with multi-billion dollar markets.
Auspex Pharmaceuticals (
is the 5th-best performing biotech IPO of 2014, and now trades 75% above its IPO price. The late-stage biotech targets chorea (associated with Huntington's disease) and other involuntary movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome.
Minerva Neurosciences (
raised $33 million in early July, and has traded up 13% after slashing its valuation by nearly half. The early-stage company focuses on symptoms of schizophrenia and depression, and also has drug candidates for insomnia and Parkinson's.
Adamas Pharmaceuticals (
now trades 11% above its IPO price after dropping 12% on the first day (the 4th-worst first-day performance for a biotech in 2014). The company raised $48 million to fund late-stage trials for generic versions of drugs that target two common CNS disorders - Parkinson's and Alzheimer's.
ReWalk Robotics (
set terms today for an IPO that could raise $50 million in two weeks. The Israeli company recently received FDA approval to market robotic exoskeletons that enable paraplegics (and, potentially, MS patients) to walk again.
The biotech window appears to remain open as we approach Labor Day weekend, as the Renaissance Capital IPO ETF (symbol:
) trades up 6.4% year-to-date and 3.8% in the past 30 days. Renaissance issues
for institutional investors before each IPO, and provides periodic
for investors interested in the IPO market.
Keywords / Tickers: IceBucketChallenge,
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.